Pages that link to "Q40976267"
Jump to navigation
Jump to search
The following pages link to What are the functional consequences of neurocognitive deficits in schizophrenia? (Q40976267):
Displaying 50 items.
- The impact of environmental factors in severe psychiatric disorders (Q21129355) (← links)
- An event-related FMRI study of phonological verbal working memory in schizophrenia (Q21136187) (← links)
- A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia (Q21203917) (← links)
- Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature (Q22241267) (← links)
- Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options (Q22241447) (← links)
- Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies (Q22251051) (← links)
- Schizophrenia, “Just the Facts”: What we know in 2008 (Q22251476) (← links)
- The myth of schizophrenia as a progressive brain disease (Q24067152) (← links)
- Selective noradrenaline reuptake inhibitors for schizophrenia (Q24197825) (← links)
- Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders (Q24532028) (← links)
- Should cognitive deficit be a diagnostic criterion for schizophrenia? (Q24597744) (← links)
- The Role of Motivation for Treatment Success (Q24613458) (← links)
- Evaluation of the clinical efficacy of asenapine in schizophrenia (Q24630385) (← links)
- Neurophysiological and Computational Principles of Cortical Rhythms in Cognition (Q24630528) (← links)
- Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition (Q24792471) (← links)
- Memory deficit in patients with schizophrenia and posttraumatic stress disorder: relational vs item-specific memory (Q26747791) (← links)
- Conscious brain, metacognition and schizophrenia (Q26749563) (← links)
- Brexpiprazole: so far so good (Q26766401) (← links)
- Phospholipase C-β1 Hypofunction in the Pathogenesis of Schizophrenia (Q26774767) (← links)
- A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings (Q26778420) (← links)
- Translational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in Schizophrenia (Q26801568) (← links)
- What does schizophrenia teach us about antipsychotics? (Q26823906) (← links)
- Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders? (Q26824270) (← links)
- Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies (Q26827100) (← links)
- Preclinical models of antipsychotic drug action (Q26827502) (← links)
- Towards medication-enhancement of cognitive interventions in schizophrenia (Q26860777) (← links)
- Update on the development of lurasidone as a treatment for patients with acute schizophrenia (Q27009585) (← links)
- Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia (Q27014120) (← links)
- Working memory training in schizophrenia and healthy populations (Q27014678) (← links)
- UPSA-M: Feasibility and initial validity of a mobile application of the UCSD Performance-Based Skills Assessment. (Q27303904) (← links)
- Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature (Q28276669) (← links)
- Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy (Q28297813) (← links)
- Muscarinic agonists for the treatment of cognition in schizophrenia (Q28301970) (← links)
- Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol (Q28362116) (← links)
- Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients (Q28372074) (← links)
- Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile (Q28389666) (← links)
- Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia (Q28483750) (← links)
- Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis (Q28540093) (← links)
- Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease (Q28660933) (← links)
- Sustaining attention to simple tasks: a meta-analytic review of the neural mechanisms of vigilant attention (Q28708997) (← links)
- Attentional processing in C57BL/6J mice exposed to developmental vitamin D deficiency (Q28730312) (← links)
- Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia (Q28744227) (← links)
- Cortical inhibitory neurons and schizophrenia (Q29547683) (← links)
- Abnormal neural oscillations and synchrony in schizophrenia (Q29619846) (← links)
- Cognition–emotion interactions in schizophrenia: Emerging evidence on working memory load and implicit facial-affective processing (Q30049296) (← links)
- Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy (Q30355399) (← links)
- A dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey. (Q30356275) (← links)
- Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome (Q30357827) (← links)
- Targeting Functional Biomarkers in Schizophrenia with Neuroimaging. (Q30366697) (← links)
- Developmental vitamin D deficiency and schizophrenia: the role of animal models. (Q30366744) (← links)